Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.6500 (-5.83%) ($5.5000 - $6.1300) on Wed. Nov. 14, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.57% (three month average) | RSI | 41 | Latest Price | $5.6500(-5.83%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -3.1% a day on average for past five trading days. | Weekly Trend | ADAP declines -0.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(17%) GDXJ(12%) JETS(11%) FXI(9%) ICLN(9%) | Factors Impacting ADAP price | ADAP will decline at least -2.785% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.785% (StdDev 5.57%) | Hourly BBV | 0 () | Intraday Trend | -6.1% | | | |
|
1 - 5 Day Possible Target | $-41.26(-830.27%) | Resistance Level | $6.88 | 5 Day Moving Average | $6.16(-8.28%) | 10 Day Moving Average | $6.48(-12.81%) | 20 Day Moving Average | $6.88(-17.88%) | To recent high | -60.1% | To recent low | 0% | Market Cap | $874m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |